AngioDynamics inks a deal to invest in EmboMedics and its ResoSphere resorbable embolic microsphere technology, with a possible acquisition on the table.
A labeling miscue prompts Covidien to recall 2 models of its Trellis clot-busting infusion device.
UPDATED Feb. 12, 2015, with new information from Medtronic.
Results from a study of Medtronic's ClosureFast varicose vein device, published this month in the British Journal of Surgery, show an 91.9% occlusion rate after 5 years.
BiO2 wins an investigational device exemption from the FDA for a pivotal trial of its Angel catheter and inferior vena cava filter in the prevention of pulmonary embolism.
BiO2 said it won an FDA nod for a pivotal trial of its Angel catheter and vena cava filter in the prevention of pulmonary embolism.
The 182-patient trial is a single-arm safety & efficacy study of the Angel device in patients at high risk for developing pulmonary embolism who can't take standard drug therapies, according to a press release.
Intravascular imaging company Infraredx files for an initial public offering worth $55 million.
Infraredx yesterday registered for an initial public offering with the Securities & Exchange Commission, estimating the flotation's worth at $55 million.
Burlington, Mass.-based Infraredx makes an imaging system that combines intravascular ultrasound and near-infrared spectroscopy to provide images of the interior of coronary blood vessels.
Vascular Solutions says the FDA granted 510(k) clearance for its Gel-Block embolization foam.
A Covidien study has shown that its new VenaSeal system is just as effective in treating chronic leg vein disorders as its ClosureFast ablation catheter.